Eli Lilly’s once-daily oral obesity drug orforglipron (branded Foundayo) won FDA approval, immediately setting up a commercial head-to-head with Novo Nordisk’s oral GLP-1 Wegovy, which has been in launch since January. Analysts and company statements highlighted the fast timeline and differentiators in dosing convenience, with Lilly emphasizing use “with or without food,” while Novo has pointed to weight-loss performance from its OASIS 4 data and is now preparing additional evidence presentations. The approval also reframes payer and access strategy, where insurers and telehealth/cash-pay channels are expected to determine share gains as the oral GLP-1 market scales. For the broader sector, the launch is another signal that obesity is moving from injectable-only growth to an increasingly competitive oral landscape, pressuring late-stage programs and compelling new trial designs for comparative outcomes.